The Ongoing Loxo Thesis, Part 2: The Journey Doesn't End With Larotrectinib

Flickr 1 week ago Flickr News 7
So let us discuss today! (Source: Go digital on So if we have this magic bullet for NTRK-positive cancers, then why are they bothering to research another Trk inhibitor, LOXO-195? And why did Bayer (OTCPK:BAYRY) buy this drug, too ...
Read The Rest at